Shaker Investments LLC OH Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Shaker Investments LLC OH raised its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 75,326 shares of the biopharmaceutical company's stock after purchasing an additional 8,249 shares during the quarter. Halozyme Therapeutics accounts for 1.5% of Shaker Investments LLC OH's portfolio, making the stock its 21st biggest position. Shaker Investments LLC OH owned 0.06% of Halozyme Therapeutics worth $3,601,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Congress Asset Management Co. raised its holdings in Halozyme Therapeutics by 446.5% during the 3rd quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock valued at $139,298,000 after buying an additional 1,988,238 shares during the last quarter. Janney Montgomery Scott LLC increased its position in shares of Halozyme Therapeutics by 698.8% in the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company's stock valued at $13,756,000 after acquiring an additional 251,711 shares during the period. Boston Trust Walden Corp boosted its holdings in shares of Halozyme Therapeutics by 54.0% during the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company's stock worth $39,073,000 after purchasing an additional 239,321 shares during the period. South Street Advisors LLC bought a new position in Halozyme Therapeutics during the 3rd quarter valued at approximately $9,812,000. Finally, Hantz Financial Services Inc. purchased a new stake in Halozyme Therapeutics in the 3rd quarter worth approximately $9,260,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.40% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, February 4th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a "market outperform" rating in a research report on Friday, November 1st. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Piper Sandler upped their target price on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Finally, Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research report on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $60.89.

Halozyme Therapeutics Stock Down 0.3 %

HALO stock traded down $0.20 during trading on Friday, hitting $58.41. 469,086 shares of the stock traded hands, compared to its average volume of 1,245,568. The stock has a market cap of $7.43 billion, a price-to-earnings ratio of 19.34, a price-to-earnings-growth ratio of 0.44 and a beta of 1.25. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a 1 year low of $35.23 and a 1 year high of $65.53. The firm's 50 day moving average is $52.09 and its two-hundred day moving average is $54.45.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.